A randomized, controlled, split-face clinical trial comparing combination of ProACNE SOLUTION ACTIVE CLEAR with 2.5% benzoyl peroxide versus 2.5% benzoyl peroxide with placebo in the treatment of mild to moderate degree of acne vulgaris

Phase 3

• Conditions: mild to moderate degree of acne vulgaris; Acne; acne vulgaris; benzoyl peroxide; salicylic acid; L- carnitine; decylene glycol; licochalcone A

• Registration Number: TCTR20171104001
• Lead Sponsor: Beiersdorf (Thailand) Co., Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-04
• Study Completion: 2018-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

- age 18 - 40 years old
- mild to moderate degree of acne vulgaris, according to Leeds revised acne grading

Exclusion Criteria

- pregnant or breast-feeding woman
- allergic to benzoyl peroxide or any ingredient of ProACNE SOLUTION ACTIVE CLEAR (salicylic acid, L-carnitine, decylene glycol, licochalcone A)
- deny to discontinue topical therapy of acne more than 14 days before starting treatment.
- denial to discontinue topical therapy of acne more than 14 days before starting treatment.
- denial to discontinue systemic therapy of acne more than 28 days before starting treatment.
- irregular menstruation or known case of PCOS

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of inflammatory acne lesions which decrease within 8 weeks 1,2,4,8 week Examination of the facial skin

Secondary Outcome Measures

Name	Time	Method
degree of acne severity 1,2,4,8 week Examination of the facial skin,skin biophysical changes (including TEWL, sebum, hydration in the skin) 1,2,4,8 week multi probe system Cutometer® dual MPA580,patient satisfaction score 1,2,4,8 week satisfaction score